Modified sophorolipids for improved bioavailability of amino acids and methods of use
By connecting amino acids and sophora lipid through amide bonds to form modified sophora lipid, the problem of insufficient bioavailability and efficacy of the existing sophora lipid is solved, and the stability and efficiency improvement under different conditions is achieved. In a variety of medical and nutritional applications.
Patent Information
- Application Number
- CN202380032667.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-08
- Filing Date
- 2023-04-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing sopholipids have shortcomings in terms of bioavailability and efficacy, especially in terms of amino acid delivery and biological activity, and it is difficult to effectively improve its stability and efficiency under different conditions.
By connecting amino acids to sophora lipids through amide bonds, the modified sophora lipid or truncated sophora lipids are enhanced, and these compounds are produced by fermentation and chemical modification methods, suitable for treatment , prevent diseases and improve nutrition.
Modified sophora lipid improves the bioavailability of amino acids and the efficacy of sophora lipid, enhances its stability under temperature, pressure and ionic strength, is suitable for the treatment of a variety of diseases and improves nutrition, and improves its in-skin. and biosurfactivity properties.
Smart Images

Figure CN119032181A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 328,883, filed on April 8, 2022, which is incorporated herein by reference in its entirety. Background Art
[0003] Sophorolipids are classified as glycolipid biosurfactants because they are produced by fermentation of microorganisms such as Starmerella bombicola using carbohydrates and lipids as carbon sources. Sophorolipids are amphiphilic molecules containing a hydrophilic carbohydrate group (sophorose) and a hydrophobic fatty acid. Sophorose is a disaccharide composed of two glucose molecules linked via a β-1,2 bond. The sophorose in sophorolipids can be acetylated, particularly at the 6' and / or 6" positions. The fatty acids in sophorolipids are attached to the sophorose molecule as β-glycosidic groups via their hydroxyl groups, and their terminal carboxylic acid groups are free (e.g. Figure 1 ) or internally esterified (ie, lactone form), generally at the 4" position. The fatty acid of the sophorolipid generally has 16 or 18 carbon atoms with one degree of unsaturation. However, it can be composed of chain lengths of C12 to C22 with different degrees of unsaturation and positions of unsaturation. Therefore, sophorolipids are often produced as a mixture of related molecules. The differences between related molecules mainly come from: their fatty acid structure (degree of unsaturation, chain length, position of unsaturation and position of hydroxylation); whether they are produced in free form or in lactone form, acetylation mode; the presence of stereoisomers; and / or whether the β-glycosidic bond on the fatty acid is located at the ω position (e.g., terminal) or the ω-1 position (close to the terminal).
[0004] Sophorolipids have many advantageous features that make them superior to synthetic surfactants, such as biodegradability, low toxicity, high surface and interfacial activity, and stability over a wide range of temperature, pressure, and ionic strength.
[0005] In recent years, efforts have been made to chemically modify sophorolipids in order to enhance their properties. One example is poly(sophorolipid), a sophorolipid polymer with potential biomaterial applications. Summary of the invention
[0006] One aspect of the invention provides amino acid modified sophorolipids or "truncated" sophorolipids. In some embodiments, the modified sophorolipids improve the bioavailability of the linked amino acids compared to the free amino acids. In other embodiments, the modified sophorolipids enhance the efficacy of the sophorolipids and / or amino acids.
[0007] According to the first group of embodiments, the present invention provides a modified sophorolipid or a salt thereof of formula (I):
[0008]
[0009] in:
[0010] R1 is an amino acid linked to the adjacent carbonyl portion of the sophorolipid structure via an amide bond;
[0011] R2 are each independently H or -COCH3;
[0012] R3 is a saturated or unsaturated aliphatic hydrocarbon chain having 5-15 carbons; and
[0013] R4 is H or -CH3.
[0014] According to a second group of embodiments, the present invention provides a modified sophorolipid or a salt thereof of formula (II):
[0015]
[0016] in:
[0017] R1 is an amino acid linked to the adjacent carbonyl portion of the sophorolipid structure via an amide bond;
[0018] R2 is each independently H or -COCH3; and
[0019] R4 is H or -CH3.
[0020] The present invention covers all compounds represented by the general formula (I) and the general formula (II), including their salts, hydrates, geometric isomers and optical isomers, and polymorphic forms thereof.
[0021] Other aspects of the invention relate to methods for improving the bioavailability of amino acids. The modified sophorolipids of the invention can effectively deliver the linked amino acids and enhance their efficacy by improving the bioavailability of the linked amino acids. In other embodiments, the modified sophorolipids enhance the efficacy of the sophorolipids and amino acids.
[0022] Additionally, certain embodiments of the present invention provide methods of treating or preventing various diseases, disorders, and / or conditions by administering modified sophorolipids.
[0023] Other embodiments of the invention are directed to methods of improving nutrition in a subject's diet by administering a modified sophorolipid in combination with an amino acid that is or may be lacking or insufficient in the subject's diet. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1An exemplary general structure of a free acid form of a sophorolipid is shown, wherein: R is each independently H or acetyl (-COCH3); R c It refers to carbon chains of typically C10 to C20 length with varying degrees and positions of unsaturation.
[0025] Figure 2 Exemplary structures of α-amino acids are shown.
[0026] Figure 3 Exemplary structures of β-amino acids are shown.
[0027] Figure 4 Exemplary structures of γ-amino acids are shown.
[0028] Figure 5 Exemplary structures of delta-amino acids are shown. DETAILED DESCRIPTION
[0029] Modified Sophorolipids
[0030] In one aspect, the present invention provides a modified sophorolipid of general formula (I), general formula (II) or a salt thereof, wherein the sophorolipid or truncated sophorolipid is linked to an amino acid via an amide bond. "Truncation" means that the carbon chain of the fatty acid is shorter than the carbon chain of the fatty acid usually present in the sophorolipid.
[0031] According to the first group of embodiments, the present invention provides a modified sophorolipid or a salt thereof of formula (I):
[0032]
[0033] in:
[0034] R1 is an amino acid linked to the adjacent carbonyl portion of the sophorolipid structure via an amide bond;
[0035] R2 are each independently H or -COCH3;
[0036] R3 is a saturated or unsaturated aliphatic hydrocarbon chain having 5-15 carbons; and
[0037] R4 is H or -CH3.
[0038] In some preferred embodiments, the modified sophorolipid of formula (I) or its salt has R3 as an aliphatic hydrocarbon chain of 8 carbons with one unsaturation in the form of a double bond, R4 as a methyl group (-CH3), and all R2 are H.
[0039] In other embodiments, the modified sophorolipid of formula (I) or a salt thereof has the following structure:
[0040]
[0041] wherein R1 is an amino acid linked to the carbonyl portion of the sophorolipid structure via an amide bond.
[0042] According to a second group of embodiments, the present invention provides a modified sophorolipid or a salt thereof of formula (II):
[0043]
[0044] in:
[0045] R1 is an amino acid linked to the adjacent carbonyl portion of the sophorolipid structure via an amide bond;
[0046] R2 is each independently H or -COCH3; and
[0047] R4 is H or -CH3.
[0048] In some preferred embodiments, the modified sophorolipid of formula (II) or a salt thereof has R4 as methyl (—CH3) and all R2 as H.
[0049] In other embodiments, the modified sophorolipid of formula (II) or a salt thereof has the following structure:
[0050]
[0051] wherein R1 is an amino acid linked to the carbonyl portion of the sophorolipid structure via an amide bond.
[0052] The present invention covers all compounds represented by the general formula (I) and the general formula (II), including salts thereof, hydrates thereof, geometric isomers thereof and optical isomers thereof, and polymorphic forms thereof. In addition, those skilled in the art will appreciate that if the amino acid of the R1 group has a free acid such as a carboxylic acid, the modified sophorolipids of formula (I) and formula (II) may exist in the form of a lactone. That is, the free carboxylic acid may be internally esterified via one of the hydroxyl substituents of the sophorose group.
[0053] In some embodiments, the modified sophorolipid improves the bioavailability of the linked amino acid compared to the free amino acid. In other embodiments, the modified sophorolipid enhances the efficacy of the sophorolipid and / or the amino acid.
[0054] Sophorolipids
[0055] Sophorolipids are generally obtained by microbial fermentation using pure fatty acids, fatty acid mixtures, pure fatty acid esters, fatty acid ester mixtures, triglycerides, and carbohydrate sources such as corn syrup, dextrin, and glucose as carbon sources using fermentation methods involving wild-type or engineered yeast strains. Figure 1As shown in , sophorolipids generally consist of sophorose, which may or may not be acetylated, particularly at the 6' and 6" positions, and hydroxylated fatty acid tails with varying degrees of unsaturation. Most commonly, the fatty acids consist of 16 or 18 carbon atoms with one degree of unsaturation, but the fatty acid structure (e.g., degree of unsaturation, chain length) varies depending on the carbon source provided during production and the microorganism being fermented.
[0056] The use of renewable substrates and different microbial species and the variation of culture parameters (incubation time, stirring speed, pH of the culture medium and added nutrients) to produce sophorolipids allows the acquisition of compounds with different structures and physical properties. This makes it possible to produce a wide variety of compounds that can induce different physical, chemical, biochemical and biophysical properties.
[0057] The hydrophobic fatty acid tail of the biosurfactant is usually hydroxylated at the terminal end and attached to the sophorose molecule in a β-glycosidic manner. Figure 1 The degree of lactonization of sophorolipids and the degree of acetylation of sophorose may be affected by the carbon source fed during the production of sophorolipids. For example, it has been found that the sophorolipids formed from rapeseed oil, sunflower oil and palm oil rich in C18:0 and C18:1 fatty acids have a higher content of diacetylated lactones than the sophorolipids produced from the corresponding fatty acid ester feedstocks.
[0058] Sophorolipids have environmental compatibility, high biodegradability, low toxicity, high selectivity, and specific activity under a wide range of temperature, pH, and salinity conditions. The proposed benefits of sophorolipids include, but are not limited to, killing pathogens in the skin, regulating the skin's immune system, killing melanocytes to allow replacement cell growth, reducing oxidative stress, enhancing the proliferation and function of keratinocytes and fibroblasts, and enhancing the skin penetration of both, for example, biosurfactants and one or more other active ingredients in the composition. See, for example, U.S. Publication No. 2020 / 0155444.
[0059] Fermentation
[0060] In some embodiments, the amino acid modified sophorolipids according to the present invention are produced by fermentation methods known in the art in the presence of selected fatty acids and carbohydrate raw materials. In other embodiments, the sophorolipids to be modified are first produced by fermentation methods known in the art, and then chemically modified using known synthetic techniques to attach the desired amino acids. As used herein, "fermentation" refers to the growth of cells under controlled conditions. Growth can be aerobic or anaerobic. Fermentation methods known in the art include, but are not limited to, solid-state fermentation, submerged fermentation or modification, hybridization and / or combinations thereof.
[0061] The modified sophorolipids or sophorolipids to be modified according to formula (I) or formula (II) of the present invention can be derived from recombinant organisms or by producing sophorolipids in a natural manner via a fermentation method. Non-limiting examples of organisms producing sophorolipids include Candida bombicola, Candida apicola, Candida bogoriensis, Yarrowia lipolytica, Starmerella bombicola, Starmerella clade, Rhodotorula bogoriensis, Wickerhamiella domericqiae and Wickerhamomyces anomalus. It is reported that some recombinant microorganisms producing sophorolipids allow control of sophorolipid structure. As a non-limiting example, certain recombinant Bombus spp. strains can be used to produce only lactone or only acidic sophorolipids (see Roelants et al., Towards the Industrialization of New Biosurfactants: Biotechnological Opportunities for the Lactone Esterase Gene from Starmerella Bombicola, 113 Biotechnology and Bioengineering 3, 550-559 (2015)). As another example, recombinant Bombus spp. strains with acetyltransferase gene knockout can be used to produce non-acetylated sophorolipids (see, e.g., WO 2012 / 080116).
[0062] The microorganisms of interest can be cultured and utilized on a small or large scale on site, even still mixed with their culture medium. The modified sophorolipids of the present invention can also be produced in large quantities at the desired location. The growth vessel for the biological growth of the sophorolipid production can be any industrial fermentation tank or culture reactor.
[0063] In one embodiment, a single type of microorganism is grown in a reactor system. In alternative embodiments, multiple microorganisms that can grow together and have no deleterious effects on growth or the products produced can be grown in a single reactor system. For example, 2 to 3 or more different microorganisms can be grown in a single reactor simultaneously. In some embodiments, more than one microorganism is grown symbiotically in a reactor.
[0064] In one embodiment, the container may have, or may be connected to, functional controls / sensors to measure important factors in the culture process, such as pH, oxygen, pressure, temperature, agitator shaft power, humidity, viscosity and / or microbial density and / or metabolite concentration.
[0065] The culture can be supplemented with a carbon source. The carbon source is typically a carbohydrate such as glucose, sucrose, lactose, fructose, trehalose, mannose, mannitol and / or maltose; an organic acid such as acetic acid, fumaric acid, citric acid, propionic acid, malic acid, malonic acid and / or pyruvic acid; an alcohol such as ethanol, isopropyl, propanol, butanol, amyl alcohol, hexanol, isobutanol and / or glycerol; fats and oils such as soybean oil, rice bran oil, rapeseed oil, olive oil, corn oil, sesame oil and / or linseed oil, etc. These carbon sources can be used independently or in a combination of two or more.
[0066] In some embodiments, the carbon source utilized in the fermentation process has been chemically modified to have a desired functional group. For example, the fatty acid may have been attached to the selected amino acid before the selected amino acid is introduced into the reaction vessel containing the microorganism producing the sophorolipid. In other embodiments, the fatty acid utilized in the fermentation process has not yet been attached to the amino acid.
[0067] A nitrogen source may be added to the culture. The nitrogen source may be, for example, potassium nitrate, ammonium nitrate, ammonium sulfate, ammonium phosphate, ammonia, urea and / or ammonium chloride. These nitrogen sources may be used independently or in a combination of two or more.
[0068] Oxygen may also be added to the growing culture in culture. One embodiment utilizes slow movement of air to remove hypoxic air and introduce oxygenated air. In the case of submerged fermentation, the oxygenated air may be ambient air that is replenished daily by a mechanical device that includes an impeller for mechanically agitating the liquid and an air sparger for supplying gas bubbles to the liquid to dissolve oxygen into the liquid.
[0069] In one embodiment, the microorganisms can be grown on solid or semisolid substrates such as flour or meal of corn, wheat, soy, chickpeas, beans, oatmeal, pasta, rice, and / or any of these or other similar substances.
[0070] In one embodiment, the growth factor and micronutrients for microorganisms are included in the culture medium. When the grown microorganisms cannot produce all the vitamins they need, this is particularly preferred. Inorganic nutrients may also be included in the culture medium, and the inorganic nutrients include trace elements, such as iron, zinc, copper, manganese, molybdenum and / or cobalt. In addition, the source of vitamins, essential amino acids and trace elements may be included, for example, in the form of flour or meal such as corn flour or in the form of extracts such as yeast extract, potato extract, beef extract, soybean extract, banana peel extract, etc. or in the form of purification. Amino acids may also be included, such as amino acids useful for the biosynthesis of proteins. Such amino acids include those amino acids that are not intended to be a part of the modified sophorolipids of formula (I) or formula (II).
[0071] In one embodiment, inorganic salts may also be included. Available inorganic salts may be potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric sulfate, ferric chloride, manganese sulfate, manganese chloride, zinc sulfate, lead chloride, copper sulfate, calcium chloride, calcium carbonate, sodium chloride and / or sodium carbonate. These inorganic salts may be used independently or in combination of two or more.
[0072] In some embodiments, when, for example, the microorganism used to inoculate the substrate is in spore form (e.g., bacterial endospores), a germination enhancer may be added to the substrate. Examples of germination enhancers according to the present invention include, but are not limited to, L-alanine, manganese, L-valine, and L-asparagine or any other known germination enhancer.
[0073] In some embodiments, additional acid and / or antimicrobial agents may be added to the liquid medium before and / or during the culture process. Antimicrobial agents or antibiotics may be used to protect the culture from contamination. In addition, defoamers may also be added to prevent the formation and / or accumulation of foam when gas is produced during the culture period.
[0074] The pH of the mixture should be appropriate for the microorganism of interest. Buffers and pH adjusters such as carbonates and phosphates can be used to stabilize the pH around the preferred value. When metal ions are present in high concentrations, it may be necessary to use a chelating agent in the liquid culture medium.
[0075] The methods and apparatus for culturing microorganisms and producing microbial byproducts can be performed in a batch, quasi-continuous, or continuous process.
[0076] In one embodiment, the microorganism culture is carried out at about 5° C. to about 100° C., preferably about 15° C. to about 60° C., more preferably about 25° C. to about 50° C. In another embodiment, the culture can be carried out continuously at a constant temperature. In another embodiment, the culture may be subjected to temperature changes.
[0077] In one embodiment, the method and the equipment used in the culture process are sterile. Culture equipment such as reactors / containers can be separated from, but connected to, a sterilization unit such as an autoclave. The culture equipment can also have a sterilization unit that is sterilized in situ before starting inoculation. The air can be sterilized by methods known in the art. For example, ambient air can pass through at least one filter before being introduced into the container. In other embodiments, the culture medium can be pasteurized, or optionally, the culture medium is not heated at all, wherein low water activity and low pH can be used to control undesirable bacterial growth.
[0078] In one embodiment, when the culture is complete (eg, when, for example, a desired cell density or density of a specified metabolite is achieved), all of the microbial culture composition is removed. In this batch procedure, after harvesting the first batch, a completely new batch is started.
[0079] In another embodiment, only a portion of the fermentation product is removed at any one time. In this embodiment, the biomass with living cells is retained in the container as an inoculant for a new culture batch. The removed composition can be a microbial-free culture medium, or contain cells, spores, mycelium, conidia or other microbial propagules. In this way, a quasi-continuous system has been created.
[0080] In some embodiments, the modified sophorolipid of formula (I) or formula (II) or the sophorolipid to be modified is produced by the microorganism of interest and retained in the microorganism or secreted into their growth medium. The modified sophorolipid or the sophorolipid to be modified can be, for example, at least 20% w / v, 30% w / v, 40% w / v, 50% w / v, 60% w / v, 70% w / v, 80% w / v or 90% w / v of the total removed composition.
[0081] The growth medium may contain compounds that stabilize the activity of the sophorolipids.The modified sophorolipids or sophorolipids to be modified may be purified, or such sophorolipids may be used in the form of crude material, meaning that they are not isolated from the fermentation broth in which they are produced.
[0082] In certain embodiments, the modified sophorolipid or sophorolipid to be modified is separated and / or purified from the growth medium, thereby causing a microbial fermentation that produces a biosurfactant. Separation and purification can be easily achieved using known methods or techniques described in the literature. The sophorolipid can be further concentrated as desired.
[0083] As used herein, the terms "isolated" or "purified" when used in conjunction with a biological or natural material, such as a glycolipid, means that the material is substantially free of other compounds with which it is essentially associated, such as cellular material. That is, the material does not occur naturally without these other compounds and / or has different or unique characteristics compared to those found in the natural material.
[0084] In certain embodiments, the purified compound is at least 60% by weight of the compound of interest. Preferably, the preparation is at least 75% (w / w), more preferably at least 90% (w / w) and most preferably at least 99% (w / w) or 100% (w / w) of the desired compound weight. Purity is measured by any appropriate standard method, for example by column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analysis.
[0085] Chemical modification method
[0086] In some embodiments, the modified sophorolipid according to the present invention is obtained by chemically modifying a sophorolipid that has been produced by a sophorolipid-producing microorganism. The sophorolipid to be chemically modified can be obtained by a fermentation method as described above and / or any other method known in the art, and then separated or purified using a known method or technique. The sophorolipid produced can be modified using any suitable technique and chemical reaction known in the art. For example, an amino acid can be connected to a sophorolipid structure via various reactions, including but not limited to amidation, reductive amination, and esterification. In a preferred embodiment, an amino acid can be connected to a sophorolipid structure via amidation, including but not limited to an amide coupling reaction.
[0087] Chemical modifications may also be carried out, for example to change the degree of unsaturation on the fatty acid chain. Well-known hydrogenation or dehydrogenation reactions, or addition or elimination reactions, with or without catalysts may be used.
[0088] Amino Acids
[0089] The modified sophorolipids of the present invention have amino acids within their structure that are connected to the fatty acid chains of the sophorolipid structure via amide bonds. In preferred embodiments, the amino acids can be released from the sophorolipid structure during its digestion to confer therapeutic, pharmaceutical, nutritional or other benefits thereon. By covalently attaching amino acids to sophorolipids or truncated sophorolipids (i.e., Formula (I) and Formula (II) respectively) via amide bonds, the amino acids can be delivered, released and absorbed by the subject's body more effectively than when the individual amino acids are administered to the subject.
[0090] As used herein, amino acids have at least one amino group and at least one acid such as a carboxyl group in their main chain and a different side chain for each amino acid. The amino group in the main chain can form an amide bond with the carbonyl portion of the sophorolipid structure of formula (I) and formula (II). The side chain can be a variety of substituents, including but not limited to organic, semi-organic or inorganic hydrogen (e.g., as in glycine) and a ring cyclized to an amine (e.g., as in proline). If a suitable amino group is present in the side chain, it can also form an amide bond with the carbonyl portion of the sophorolipid structure of formula (I) and formula (II). The amino group and the acid (e.g., carboxyl group) of the main chain can be attached to the same carbon (α-carbon) or different carbons.
[0091] It is also within the spirit and scope of the present invention that an amino acid contains an acidic group in addition to a carboxyl group in its backbone. For example, a sulfonic acid or a thiocarboxylic acid (i.e., one in which one of the oxygen atoms is replaced by a sulfur atom) may be present in the amino acid structure in place of the carboxyl group. A non-limiting example of such an amino acid is taurine (also known as 2-aminoethanesulfonic acid), which contains a sulfonic acid and an amino group attached to the β-carbon.
[0092] As used herein, amino acids may be L-amino acids or D-amino acids. They may be natural amino acids (such as essential amino acids, non-essential amino acids or conditional amino acids) or synthetic / modified amino acids that do not exist in nature. The present invention encompasses both amino acids incorporated into proteins and amino acids that are not incorporated into proteins. Amino acids present in nature may be purified products, or may be artificially synthesized.
[0093] In aqueous solution, amino acids—especially the common natural forms of amino acids—exist as zwitterions, in which both the amino group and the acid (e.g., carboxyl group) are charged, e.g., NH3 + or—NH2 + ,—and—CO2 - Depending on the pH of the environment, certain side chains may also exist in a charged state.
[0094] In some embodiments, the amino acids according to the invention are α-amino acids. Exemplary structures are depicted in Figure 2 In the embodiment of the present invention, it contains an amino group and a carboxyl group attached to the same carbon, the carbon adjacent to the carboxyl group being designated as the α-carbon. Substituents X and Y are also attached to the α-carbon, they may be the same or different, and at least one of them is typically H. The amino group may be a primary amine, where Q is H, or substituted, where Q is a substituent. Non-limiting examples of α-amino acids include glycine, methionine, lysine, and glutamine.
[0095] In other embodiments, the amino acids according to the invention are β-amino acids. Figure 3 In the embodiment of the present invention, it contains an amino group attached to the β-carbon (the second carbon from the carboxyl group). X, Y, W and Z can be any substituents, which can be the same or different, and at least one of which is typically H. The amino group can be a primary amine, where Q is H, or substituted, where Q is a substituent. Non-limiting examples of β-amino acids include β-alanine and taurine.
[0096] In yet other embodiments, the amino acids according to the invention are γ-amino acids. Figure 4 In the invention, it contains an amino group attached to the γ-carbon (the third carbon from the carboxyl group). X, Y, W, Z, A and G can be any substituents, which can be the same or different, and at least one of which is typically H. The amino group can be a primary amine, where Q is H, or substituted, where Q is a substituent. Non-limiting examples of γ-amino acids include vigabatrin (4-amino-5-hexenoic acid) and γ-aminobutyric acid (GABA).
[0097] In other embodiments, the amino acids according to the invention are delta-amino acids. Exemplary structures are depicted in Figure 5 In the embodiment of the present invention, it contains an amino group attached to the delta-carbon (the fourth carbon from the carboxyl group). X, Y, W, Z, A, G, J and L can be any substituents, which can be the same or different, and at least one of which is usually H. The amino group can be a primary amine, where Q is H, or substituted, where Q is a substituent. Non-limiting examples of delta-amino acids include 5-aminopentanoic acid and 5-amino-2-oxopentanoic acid.
[0098] Those skilled in the art will appreciate that the general structure of amino acids may be further modified without departing from the spirit and scope of the present invention. For example, the carbon chain of the main chain between the amino group and the acid may be longer than the carbon chain of the delta-amino acids described above, or the acid may be esterified.
[0099] In some embodiments, the amino acid incorporated into the modified sophorolipid according to the present invention is methionine (Met), lysine (Lys) or glutamine (Gln). In specific embodiments, these modified sophorolipids are used to reduce factors that cause stress to the subject, such as reactive oxygen species (ROS) and cortisol.
[0100] Methionine (Met) is an essential amino acid and a key precursor of the cell methyl donor S-adenosylmethionine. Methionine residues in proteins react easily with a variety of reactive oxygen species (ROS), thereby removing active species. After the reaction, methionine forms methionine sulfoxide, which can be reduced back to methionine in the cell. Therefore, methionine residues can serve as catalytic antioxidants, thereby protecting both proteins and other macromolecules to which they are located, including the cells themselves. It is also believed that methionine provides health benefits, including the absorption of auxiliary nutrients such as selenium and zinc, promoting the excretion of heavy metals, preventing excessive fat accumulation in the liver, and reducing cholesterol levels by increasing the production of lecithin in the liver. It is also shown that methionine can effectively treat Tylenol (Tylenol) (acetaminophen) poisoning.
[0101] Lysine (Lys) is an essential amino acid and has been shown to act as a partial antagonist of some 5-hydroxytryptamine receptors 4 (5-HT4), thereby reducing blood cortisol (the so-called "stress hormone") levels and reducing stress-induced brain-gut reactions. In experimental animals, chronic dietary lysine deficiency increases stress-induced anxiety. Lysine supplementation has been shown to reduce anxiety in people with low dietary intake of L-lysine. In a study conducted on otherwise healthy adults, oral treatment with a combination of L-lysine and L-arginine reduced both trait anxiety and stress-induced state anxiety. In addition, the combination reduced the basal levels of salivary cortisol and chromogranin-A (a salivary marker of the sympathetic adrenal system) in male subjects. See, for example, Smigra, M. et al., Oral Treatment with L-lysine and L-arginine Reduces Anxiety and Basal Cortisol Levels in Healthy Humans, Biomed Res. 28 (2), 85-90 (2007). Therefore, it has been suggested that lysine supplementation is an effective anxiety and stress reducer.Lysine supplementation has also been implicated in a variety of other health benefits, including the inhibition of cold sores, calcium absorption and retention, and wound healing.
[0102] Glutamine (Gln) is a conditional amino acid. This means that glutamine can be synthesized by the body under normal physiological conditions, but under pathological conditions, the body's increased demand can cause a relative lack of glutamine. Glutamine has anti-inflammatory and antioxidant properties, which makes it a useful supplement for subjects such as athletes who engage in strenuous physical activities in highly stressful environments. Insufficient glutamine levels can lead to energy metabolism disorders, immunosuppression and increased oxidative stress.
[0103] In other embodiments, the amino acid incorporated into the modified sophorolipid according to the present invention is taurine. Taurine is a conditionally essential amino acid that is known to have antioxidant properties and to play many physiological functions in the body. Non-exhaustive examples of taurine functions are discussed below. Modified sophorolipids incorporating taurine can be used to treat a variety of ailments and / or maintain a general sense of well-being.
[0104] First, various studies have shown that taurine supplementation can delay the onset and progression of atherosclerosis and / or play a preventive role in other cardiovascular conditions and diseases. For example, reduced cholesterol levels and inflammation have been observed in patients with heart failure. Ahmadian, M., Taurine Supplementation Has Anti-atherogenic and Anti-inflammatory Effects Before and After Incremental Exercise in Heart Failure, Ther. Adv. Cardiovasc. Dis. 11(7): 185–194 (2017). In addition, taurine supplementation has an antihypertensive effect on prehypertension and significantly improves endothelium-dependent vasodilation and endothelium-independent vasodilation. Sun, Q. et al., Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension, Hypertension 67, 541-549 (2016). Taurine's ability to lower blood pressure combined with its anti-inflammatory effects make it a viable protective agent against coronary heart disease.
[0105] Taurine is also present in high levels in mammalian skeletal muscle. It is believed that taurine controls muscle metabolism and gene expression. Changes in intracellular taurine content in skeletal muscle are associated with different pathophysiological conditions such as disuse-induced muscle atrophy, muscular dystrophy and / or aging. Taurine supplements have the therapeutic potential to restore skeletal muscle function and capacity. In addition, taurine treatment can be beneficial in alleviating sarcolemmal hyperexcitability in myotonia-related syndromes. De Luca, A., Taurine: the appeal of a safe amino acid for skeletal muscle disorders, J. Transl. Med. 13, 243 (2015). Taurine supplements can also improve athletic ability, thereby, for example, improving time performance in long-distance running.
[0106] Similarly, taurine has been found to induce the expression of connective tissue growth factor (CTGF) in osteoblasts, suggesting a role for taurine in connective tissue strength.
[0107] Additional benefits of taurine supplementation involve the central and peripheral nervous systems. Taurine is required for the development and functioning of the central and peripheral nervous systems, where it plays osmoregulatory, neuromodulatory, and anti-apoptotic roles. Taurine deficiency may lead to several neurological deficits and sensory loss. Animal studies have shown that taurine helps mitigate symptoms of neurotoxicity and neurological deficits in rodents. It has also been proposed that taurine can improve or protect brain function, particularly learning and memory.
[0108] Taurine can also be used as a treatment for eye conditions such as glaucoma and diabetic retinopathy, and for the treatment of diabetes to reduce glucose levels and insulin resistance.
[0109] Other non-limiting examples of amino acids that can be used in the present invention include, but are not limited to, alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, homocysteine, glutamic acid, glycine, histidine, homotaurine, isoleucine, leucine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, theanine, D-2-amino-3-guanidinopropionic acid, GABA, citrulline, tranexamic acid, aminocaproic acid, 4-amino-5-hexenoic acid, 4-oxaproline, 4-thioproline, 2-azaproline, 4- Hydroxyproline, 1,5-disubstituted tetrazoles, 2-aminoisobutyric acid, sarcosine, 1-aminocyclopentane-1-carboxylic acid, β-alanine, 2-amino-cyclopentanecarboxylic acid (β-proline), 5-hydroxylysine, hydroxylysine-5-sulfate, hydroxylysine-5-nitrate, hydroxylysine-5-phosphate, serine-3-sulfate, threonine-3-sulfate, serine-3-nitrate, threonine-3-nitrate, serine-3-phosphate, threonine-3-phosphate, 2-hydroxyalkanoic acid, 5-aminovaleric acid and 5-amino-2-oxopentanoic acid.
[0110] The administration of the modified sophorolipids according to the present invention provides a range of benefits, depending on the amino acids incorporated therein. Various amino acids regulate glucose and lipid metabolism and energy balance, increase mitochondrial biosynthesis, and maintain immune homeostasis. Dietary amino acids are also the main irritant (fuel) of the small intestinal mucosa and an important substrate for the synthesis of intestinal proteins, nitric oxide, polyamines and other products of biological importance. Studies support that amino acids (including glutamine, glutamic acid, arginine, glycine, lysine, threonine and / or sulfur-containing amino acids) have a therapeutic effect in intestinal related diseases. For example, glutamine intake has been shown to improve intestinal health by supporting intestinal microbiome, intestinal mucosal wall integrity and by regulating inflammatory responses.
[0111] Pharmaceutically or cosmetically acceptable salts
[0112] In some embodiments, the modified sophorolipids of the present invention are provided in the form of pharmaceutically or cosmetically acceptable salts. In specific embodiments, the acid groups of the amino acids incorporated into the modified sophorolipids can be deprotonated to form salts. If the side chains of the amino acids contain appropriate functional groups, they can also form corresponding salts. Salts can be formed by procedures well known and described in the art.
[0113] Examples of pharmaceutically acceptable cations for salts include, but are not limited to, aluminum, arginine, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediamine, lysine, magnesium, histidine, lithium, meglumine, potassium, procaine, sodium, triethanolamine, and zinc. Preferred salts are lithium (Li) + ), sodium (Na+ ) and potassium (K + )Salt.
[0114] Depending on the chemical characteristics of the amino acids in the modified sophorolipids, acid addition salts can be formed. Examples of pharmaceutically acceptable addition salts include, but are not limited to, non-toxic inorganic and organic acid addition salts such as acetate derived from acetic acid, aconitate derived from aconitic acid, ascorbate derived from ascorbic acid, benzenesulfonate derived from benzenesulfonic acid, benzoate derived from benzoic acid, cinnamate derived from cinnamic acid, citrate derived from citric acid, enbolate derived from enbolate, enanthate derived from enanthic acid, and succinate derived from succinic acid. The invention also includes but is not limited to the following: enantate derived from formic acid, formate derived from formic acid, fumarate derived from fumaric acid, glutamate derived from glutamic acid, glycolate derived from glycolic acid, hydrochloride derived from hydrochloric acid, hydrobromide derived from hydrobromic acid, lactate derived from lactic acid, maleate derived from maleic acid, malonate derived from malonic acid, mandelate derived from mandelic acid, methanesulfonate derived from methanesulfonic acid, naphthalene-2-sulfonate derived from naphthalene-2-sulfonic acid, nitrate derived from nitric acid, perchlorate derived from perchloric acid, phosphate derived from phosphoric acid, phthalate derived from phthalic acid, salicylate derived from salicylic acid, sorbate derived from sorbic acid, stearate derived from stearic acid, succinate derived from succinic acid, sulfate derived from sulfuric acid, tartrate derived from tartaric acid, p-toluenesulfonate derived from p-toluenesulfonic acid, and the like.
[0115] Other salts that might not be considered pharmaceutically acceptable may be used to prepare salts useful as intermediates in obtaining the modified sophorolipids of the present invention and pharmaceutically acceptable salts thereof.
[0116] In another embodiment, according to the invention, the modified sophorolipids of the invention are used in their respective acid form.
[0117] The modified sophorolipids of the present invention can be provided in a non-solvated or solvated form with a pharmaceutically acceptable solvent such as water, ethanol, etc. The solvated form may also include a hydrated form such as a monohydrate, a dihydrate, a hemihydrate, a trihydrate, a tetrahydrate, etc.
[0118] Composition
[0119] Another aspect of the present invention relates to a composition comprising a modified sophorolipid of the present invention administered to a subject. Such compositions may be cosmetic, pharmaceutical, dietary, nutritional, etc. In some embodiments, the modified sophorolipid according to the present invention serves as an active ingredient in the composition.
[0120] As used herein, the term "subject" or "patient" describes an organism, including a mammal, such as a primate. Mammalian species that may benefit from the disclosed treatment methods include, but are not limited to, apes, chimpanzees, orangutans, humans, and monkeys; domestic animals, such as dogs, cats; livestock, such as horses, cows, pigs, sheep, goats, and chickens; and other animals, such as mice, rats, guinea pigs, and hamsters.
[0121] The specific mode of administration and the dosing regimen designed to deliver an effective amount of the modified sophorolipid are appropriately determined taking into account factors such as the nature of the amino acid, the age, sex and details of the subject, and the pathology, disease and disease state involved and whether the purpose is preventive. As used herein, the terms "effective amount" and "effective dose" are used to refer to the amount of something (e.g., compound, composition, time) that can produce the desired result (e.g., lowering cortisol levels, lowering blood pressure). The administration of an effective amount of the modified sophorolipid can be completed in the form of a daily or multi-day dose of the modified sophorolipid over a period of days to months or even years. If the modified sophorolipid is administered with another therapeutic agent, the effective amount of the modified sophorolipid can carry an amino acid, the range of which is the same as the typical range of the amino acid used as a monotherapy, or the amount can be lower than the typical monotherapy amount, especially in the case where the combination therapy causes a synergistic effect.
[0122] The composition according to the invention may comprise a modified sophorolipid in an isolated and / or purified form as an active ingredient. In other embodiments, the modified sophorolipid in the composition according to the invention is provided together with the fermentation broth in which they are produced. Such a "crude form" may comprise, for example, at least 20% w / v, 30% w / v, 40% w / v, 50% w / v, 60% w / v, 70% w / v, 80% w / v or 90% w / v of the modified sophorolipid in the fermentation broth.
[0123] The composition may also include additional active or inactive ingredients appropriate to the mode of administration and intended purpose, provided that such additions do not adversely interfere with the function of the modified sophorolipid.
[0124] In other embodiments, acceptable carriers may be included in the compositions of the present invention, depending on the form and / or mode of administration of the compositions. Pharmaceutically or cosmetically acceptable carriers include, but are not limited to, pharmaceutically acceptable excipients, such as inert diluents, disintegrants, adhesives, lubricants, sweeteners, flavoring agents, coloring agents, and preservatives. Suitable inert diluents include sodium carbonate and calcium carbonate, sodium phosphate and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrants. Adhesives may include starch and gelatin, while lubricants (if present) may generally be magnesium stearate, stearic acid, or talcum. If desired or suitable, coating materials such as glyceryl monostearate or glyceryl distearate may also be used, for example, to delay gastrointestinal absorption (as appropriate), and pharmaceutical compositions may be in the form of solid forms.
[0125] In certain embodiments, the compositions according to the present invention further comprise microbial growth byproducts. In certain embodiments, the microbial growth byproducts are amphiphilic molecules, enzymes and / or proteins. In one embodiment, the microbial growth byproducts have antimicrobial and / or anti-biofilm properties.
[0126] In certain embodiments, the composition further comprises one or more amphiphilic molecules, wherein the amphiphilic molecules are selected from the following biosurfactants: for example, low molecular weight glycolipids (e.g., sophorolipids, rhamnolipids, mannoerythritol lipids and trehalolipids), lipopeptides (e.g., surfactins, iturin, fengyrin, arthrofactin and lichenin), cellobiose lipids, flavolipids, phospholipids (e.g., cardiolipin) and high molecular weight polymers (such as lipoproteins, lipopolysaccharide-protein complexes and polysaccharide-protein-fatty acid complexes). The amphiphilic molecules can be modified forms, derivatives, fractions, isoforms, isomers or subtypes of biosurfactants, including biologically modified or synthetically modified forms. In one embodiment, one or more biosurfactants are present in the composition at a critical micelle concentration (CMC).
[0127] The composition can be placed in a container of appropriate size, taking into account, for example, the intended use, the intended method of administration, the size of the fermentation vessel, and any mode of transport from the microbial growth facility to the location of use. Thus, the container in which the composition is placed can be, for example, 0.1 gallons to 1,000 gallons or larger. The composition can also be placed in smaller containers such as bottles for dispensing individual doses of the composition.
[0128] The composition according to the present invention can be in various physical forms. In some embodiments, the composition is in solid form, including tablets, filled capsules, powders and pellets. In another embodiment, the pharmaceutical composition can be in the form of a powder, wherein the pharmaceutically acceptable carrier is a finely divided solid mixed with a finely divided active ingredient, i.e., a modified sophorolipid. In another embodiment, the pharmaceutical composition according to the present invention is a sustained release system, such as a semipermeable matrix of a solid hydrophobic polymer containing a modified sophorolipid of the present invention. In another embodiment, the pharmaceutical composition is in liquid form, such as an aqueous or non-aqueous solution, a suspension, an emulsion, an elixir and a capsule filled with the pharmaceutical composition.
[0129] Any suitable mode of administration can be used to administer a composition comprising the modified sophorolipid according to the present invention. Such modes include, but are not limited to, oral, rectal, bronchial, nasal, external, buccal, sublingual, transdermal, vaginal, intramuscular, intraperitoneal, intravenous, intraarterial, subcutaneous, intracerebral, intraocular administration or in a form suitable for administration (including powder and liquid aerosol administration) by suction or insufflation or parenteral infusion. It can also be administered by other carriers or vehicles such as patches, micelles, liposomes, vesicles, implants (e.g., microimplants), synthetic polymers, etc. The factors determining the mode of administration of a particular composition include the properties of the amino acids being delivered to the subject. In some embodiments, the mode of administration is oral. In other embodiments, the mode of administration is rectal.
[0130] The composition for oral administration according to the invention is any preparation or composition suitable for consumption, suitable for obtaining nutrition, suitable for obtaining oral hygiene and / or suitable for obtaining pleasure, and is a product intended to be introduced into the oral cavity of a human or animal, to remain there for a certain period of time, and then to be swallowed (e.g., food prepared for consumption) or to be removed from the oral cavity again (e.g., chewing gum or oral hygiene products or medical mouthwashes). These products include all substances or products intended to be ingested by humans or animals in a processed, semi-processed or unprocessed state. This also includes substances added to orally edible products (especially food and pharmaceutical products) during their production, handling or processing and intended to be introduced into the oral cavity of a human or animal.
[0131] In certain embodiments, the composition can also include components such as energy sources, nutrients and / or other health-promoting supplements, flavorings, preservatives, pH adjusting agents, sweeteners and / or dyes. The composition can also be carbonized. In one embodiment, the composition is formulated as a dehydrated powder or concentrate, which can be reconstituted into a drinkable fluid by adding water. In one embodiment, the composition is formulated as a mixed smoothie or milkshake.
[0132] Orally administered compositions may also include materials intended to be swallowed by humans or animals and then digested in an unmodified, prepared or processed state; therefore, orally administered compositions according to the present invention also include enteric coatings, coatings or other encapsulations that are also intended to be swallowed or expected to be swallowed together with the product.
[0133] In other embodiments, the composition according to the invention is formulated for direct administration into the gastrointestinal tract. For example, the composition can be formulated for administration to the proximal lower gastrointestinal tract by hand or colonoscopy, to the distal lower gastrointestinal tract via enema or rectal tube, and to the upper gastrointestinal tract via nasogastric tube, duodenal tube, and endoscopy / gastroscopy.
[0134] In certain embodiments, the present invention provides a topical skin care composition comprising one or more modified sophorolipids according to the present invention. In some embodiments, the topical composition may also include a dermatologically acceptable carrier and one or more active or inactive cosmetic ingredients such as vitamins, moisturizers, dyes, fragrances, sunscreens, exfoliants, essential oils, plant extracts, etc.
[0135] The dermatologically acceptable carrier may include, for example, water; saline; physiological saline; ointments; creams; oil-in-water emulsions; water-in-oil emulsions; silicone-in-water emulsions; water-in-silicone emulsions; wax-in-water emulsions; water-oil-water triple emulsions; microemulsions; gels; vegetable oils; mineral oils; ester oils such as octyl palmitate, isopropyl myristate, and isopropyl palmitate; ethers such as dicaprylyl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol, and behenyl alcohol; isoparaffins such as isooctane, isododecane, and isobutylene glycol. Hexadecane; silicone oils such as cyclomethicone, dimethicone, dimethicone crosspolymers, polysiloxanes and their derivatives, preferably organically modified derivatives, including PDMS, dimethicone copolyols, dimethicone alcohol and aminodimethicone alcohol; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyolefins (e.g. (hydrogenated) polyisobutylene); polyols such as propylene glycol, glycerol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol; waxes such as beeswax, carnauba, ozokerite, microcrystalline wax, polyethylene wax and vegetable wax; or any combination or mixture of the foregoing. The aqueous carrier may include one or more water-miscible solvents, including lower alcohols such as ethanol, isopropanol, etc. The carrier may account for about 1% to about 99%, 10% to about 85%, 25% to 75%, or 50% to about 65% by weight of the total composition.
[0136] Non-biological surfactants can also be added to the formulation. Examples of surfactants include, but are not limited to, alkyl sulfates, alkyl ether sulfates (e.g., sodium / ammonium lauryl sulfate and sodium / ammonium laureth sulfate), amphoterics (e.g., amphoacetates and amphopropionates), sulfosuccinates, alkyl polyglucosides, betaines (e.g., cocamidopropyl betaine), sulfobetaines, sacrosinates, isethionates, taurates, ethoxylated sorbitan esters, alkanolamides, and amino acid-based surfactants.
[0137] Viscosity modifiers may also be added to the composition, including, for example, cocamide DEA, oleamide DEA, sodium chloride, cellulosic polymers, polyacrylates, ethoxylated esters, alcohols, ethylene glycol, xylene sulfonates, polysorbate 20, alkanolamides, and cellulose derivatives such as hydroxypropyl methylcellulose and hydroxyethyl cellulose.
[0138] Polymers may also be added, including, for example, xanthan gum, guar gum, polyquaternium-10, PEG-120 methyl glucose dioleate, PEG-150 distearate, PEG-150 polyglyceryl-2 tristearate, and PEG-150 pentaerythritol tetrastearate.
[0139] In one embodiment, the composition may include additional skin actives, including but not limited to keratolytic agents, desquamating agents, keratinocyte proliferation enhancers, collagenase inhibitors, elastase inhibitors, depigmenting agents, anti-inflammatory agents, steroids, anti-acne agents, antioxidants (e.g., ascorbic acid), inhibitors of advanced glycation end products (AGE), exfoliants (e.g., glycolic acid, 3,6,9-trioxaundecane dioic acid, etc.), estrogen synthase stimulating compounds (e.g., caffeine and derivatives), compounds capable of inhibiting 5α-reductase activity (e.g., linolenic acid, linoleic acid, finasteride, and mixtures thereof), barrier function enhancers (e.g., ceramides, glycerides, cholesterol and esters thereof, α-hydroxy fatty acids and ω-hydroxy fatty acids and esters thereof), retinoids, and sunscreens, to name a few.
[0140] The composition may optionally include additives, adjuvants, or other components of topical compositions known to those skilled in the art, including, but not limited to: skin penetration enhancers; emollients (e.g., isopropyl myristate, petrolatum, volatile or non-volatile silicone oils (such as methicone and dimethicone), ester oils, mineral oils, and fatty acid esters); humectants (e.g., glycerol, hexylene glycol, caprylyl glycol); skin plumpers (e.g., palmitoyl oligopeptides, collagen, collagen and / or glycosaminoglycan (GAG) enhancers); anti-inflammatory agents (e.g., aloe vera, bioflavonoids); ketone, diclofenac, salicylic acid); chelating agents (e.g., EDTA or its salts, such as disodium EDTA); vitamins (e.g., tocopherol and ascorbic acid); vitamin derivatives (e.g., ascorbyl monopalmitate, tocopheryl acetate, vitamin E palmitate); thickeners (e.g., hydroxyalkyl cellulose, carboxymethyl cellulose, carbomer, and vegetable gums (such as xanthan gum)); gelling agents (e.g., ester-terminated polyesteramides); structurants; proteins (e.g., lactoferrin); immunomodulators (e.g., corticosteroids and nonsteroidal immunomodulators). Other examples include, but are not limited to: stabilizers; fragrances; film formers; insect repellents; skin cooling compounds; skin protectants; lubricants; preservatives; pearls; chromalite; mica; conditioning agents; antiallergics; pH adjusters; and antimicrobial agents.
[0141] The composition may be formulated as a suspension, emulsion, hydrogel, multiphase solution, vesicular dispersion, or in any other known form of topical skin composition.
[0142] In certain embodiments, the topical composition can be formulated so that it can be applied, for example, via a pen, tube, bottle, brush, stick, sponge, cotton swab, wipes (wipes), sprayer, dropper, hand, or fingers.
[0143] The topical composition can be formulated into a variety of product forms such as lotions, creams, serums, sprays, aerosols, liquid cakes, ointments, essences, gels, pastes, patches, pens, powders, wipes, soaps or other cleansers, shampoos, conditioners, sticks, foams, mousses, elixirs, or concentrates.
[0144] In one embodiment, the composition can be provided in the form of a facial mask. The facial mask can be a peel-off facial mask or a wash-off facial mask comprising the composition of the present invention.
[0145] In other embodiments, the compositions of the present invention can be provided in a wound dressing, bandage or patch that can be applied, attached or bonded to one or more layers of skin or tissue of a subject. For example, the composition can be applied to a wound dressing, bandage or patch that can then be placed over the skin area being treated.
[0146] Wound dressing, bandage and patch can be for example made by any material that is acceptable and suitable for being placed on wound or skin in dermatology.In exemplary embodiments, wound dressing, bandage and patch can be made by weaving or nonwoven fabric of synthetic fiber or non-synthetic fiber or their any combination.Dressing can also include support, such as can absorb composition or have arranged composition thereon polymer foam, natural or artificial sponge, gel or film.For example, support can be film, natural or synthetic polymer or rigidity or ductility material (for example, gauze).Wound dressing, bandage and patch can be absorbent, and can for example be moistened with composition of the present invention before gauze is applied to wound, scar or other positions.
[0147] In one embodiment, a wound dressing, bandage or patch may be impregnated with a composition of the invention and optionally dried. This allows the impregnated material to be stored for subsequent use, or to avoid excessive wetting of the skin.
[0148] In other embodiments, the pharmaceutical composition can be formulated for parenteral administration (e.g., by injection, such as bolus injection or continuous infusion). In addition, the composition can be present in ampoules, pre-filled syringes and small volume infusion devices in unit dosage form, or in multi-dose containers with or without preservatives. The composition can be in the form of suspensions, solutions or emulsions in oily or aqueous vehicles. The composition can also contain preparations such as suspending agents, stabilizers and / or dispersants. In another embodiment, the active ingredient of the composition according to the present invention can be in powder form, obtained by sterile separation of sterilized solids before use or by freeze-drying from a solution composed of pyrogen-free water for example sterilization with a suitable carrier.
[0149] In other embodiments, the pharmaceutical composition can be formulated for direct administration to the nasal cavity by conventional means, for example, with a dropper, a pipette or a sprayer. The composition can be provided in a single dose or multiple doses. It is also possible to achieve administration to the respiratory tract by an aerosol formulation, wherein the active ingredient is provided in a pressurized bag with a suitable propellant such as chlorofluorocarbon (CFC), for example dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane, carbon dioxide or other suitable gases. Aerosols can also conveniently contain surfactants, such as lecithin.
[0150] Methods to improve bioavailability, physiological function and nutrition
[0151] One aspect of the present invention relates to a method for improving the bioavailability, preferably oral bioavailability, of an amino acid in a subject. The method comprises providing a modified sophorolipid or salt thereof of formula (I) and / or formula (II) as described herein, wherein R1 is an amino acid attached to the carbonyl portion of the sophorolipid structure via an amide bond. In particular, the modified sophorolipid of the present invention is capable of carrying one amino acid per molecule, wherein the amino acid is attached to the carbonyl portion of the sophorolipid structure via an amide bond. Suitable amino acids have a chemical structure as described herein having at least one amino functional group capable of forming an amide bond together with the carbonyl portion at the specified attachment point of formula (I) and formula (II).
[0152] According to certain embodiments of the present invention, the modified sophorolipids are capable of enhancing and amplifying the beneficial effects of the amino acids to which they are attached. Specifically, the modified sophorolipids or their salts of formula (I) and formula (II) with amino acids contribute to more efficient and successful absorption of amino acids by the target body when administered orally. Without being bound by theory, the bioavailability of amino acids can be enhanced by, for example, inhibiting P-glycoprotein and / or regulating other physical barrier mechanisms that would otherwise reduce the penetration of amino acids, such as penetrating into epithelial cells of a subject or passing through the blood-brain barrier. Additionally or alternatively, bioavailability can be enhanced by protecting amino acids from degradation during storage or in vivo. Additionally or alternatively, bioavailability can be enhanced by improving the solubility or emulsifiability of amino acids in the composition before administration or in vivo after administration because the amino acids are attached to the sophorolipid structure.
[0153] In other embodiments, the modified sophorolipids enhance the efficacy of the sophorolipids as well as the amino acids.
[0154] Depending on the nature and action of the amino acids carried in the modified sophorolipids of the present invention, various diseases, ailments and / or conditions can be treated or prevented.
[0155] As used herein, the term "treatment" refers to eradicating, alleviating, relieving or reversing the extent, signs or symptoms of a condition or disorder to any extent, and includes but does not require complete cure of the condition or disorder. Treatment can be curing, ameliorating or partially alleviating the disorder.
[0156] As used herein, "preventing" a condition or disorder refers to avoiding, delaying, preempting or minimizing the onset of a particular sign or symptom of the condition or disorder. Prevention can be, but is not required to be, absolute or complete, meaning that the sign or symptom may still occur at a future time. Prevention can include reducing the severity of the onset of such a condition or disorder, and / or inhibiting the condition or disorder from developing into a more serious condition or disorder.
[0157] One aspect of the present invention relates to a method for reducing stress factors in a subject, the method being performed by orally administering to the subject a modified sophorolipid or a salt thereof of formula (I) and / or formula (II), wherein R1 is methionine, lysine and / or glutamine connected to the carbonyl portion of the sophorolipid structure via an amide bond. Stress factors may include biomarkers of oxidative stress known to those skilled in the art, such as those disclosed in: Katerji M., Approaches and Methods to Measure Oxidative Stress in Clinical Samples: Research Applications in the Cancer Field, Oxid. Med. Cell. Longev. 2019 (2019).
[0158] Other aspects of the present invention relate to a method for treating or preventing a muscle disorder or disease in a subject, the method being performed by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine attached to the carbonyl portion of the sophorolipid structure via an amide bond. The muscle disorder or disease may be, for example, disuse-induced muscle atrophy, muscular dystrophy and / or aging, and myotonia-related syndromes, as well as myometrial hyperexcitability.
[0159] In some embodiments, the present invention provides a method for increasing muscle activity in a subject, the method being performed by orally administering to the subject a modified sophorolipid or a salt thereof of formula (I) and / or formula (II), wherein R1 is taurine connected to the carbonyl portion of the sophorolipid structure via an amide bond. Muscle activity can be assessed by measuring the subject's muscle volume, muscle strength, muscle power and / or muscle endurance.
[0160] Still other aspects of the present invention relate to a method for treating or preventing a cardiovascular disorder or disease in a subject, the method being performed by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond. The cardiovascular disorder or disease may be, for example, atherosclerosis, hyperhomocysteinemia, cardiomyopathy, and coronary heart disease.
[0161] In some embodiments, the present invention provides a method for improving cardiovascular activity in a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond. Improvements can be observed, for example, in the subject's blood pressure, heart rate, and blood vessels.
[0162] Other aspects of the present invention relate to a method of treating or preventing hypertension in a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond.
[0163] Other aspects of the present invention relate to a method for treating or preventing a central nervous system or peripheral nervous system disorder or disease in a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond. The central nervous system or peripheral nervous system disorder or disease may be, for example, memory loss and Alzheimer's disease.
[0164] In some embodiments, the present invention provides a method for improving the function of the central nervous system or peripheral nervous system of a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine attached to the carbonyl portion of the sophorolipid structure via an amide bond. Improvements can be seen, for example, in the subject's memory retention or motor skills.
[0165] Additional aspects of the present invention relate to methods of treating or preventing a connective tissue disorder or disease in a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II) or a salt thereof, wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond.
[0166] Other aspects of the invention relate to methods of strengthening connective tissue in a subject by orally administering to the subject a modified sophorolipid of formula (I) and / or formula (II), wherein R1 is taurine linked to the carbonyl portion of the sophorolipid structure via an amide bond.
[0167] Other embodiments of the invention are directed to methods of improving nutrition in a subject's diet by administering a modified sophorolipid in combination with an amino acid that is or may be lacking or insufficient in the subject's diet.
[0168] In some embodiments, the various methods according to the present invention require a modified sophorolipid or salt thereof of formula (I) and / or formula (II) in a composition in solid form, including tablets, filled capsules and pellets. In another embodiment, the pharmaceutical composition may be in the form of a powder, wherein the pharmaceutically acceptable carrier is a finely divided solid mixed with a finely divided active ingredient, i.e., a modified sophorolipid. In another embodiment, the pharmaceutical composition according to the present invention is a sustained release system, such as a semipermeable matrix of a solid hydrophobic polymer containing a modified sophorolipid of the present invention. In another embodiment, the pharmaceutical composition is in liquid form, such as an aqueous or non-aqueous solution, a suspension, an emulsion, an elixir and a capsule filled with the pharmaceutical composition.
[0169] The transitional term "comprising," which is synonymous with "including" or "containing," is inclusive or open-ended, and does not exclude additional, unrecited elements or method steps. In contrast, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to the specified materials or steps "and materials or steps that do not materially affect the basic and novel characteristics of the claimed invention, such as the ability to improve the bioavailability of a substance." Use of the term "comprising" contemplates other embodiments of "consisting of" or "consisting essentially of" the recited components.
[0170] Unless specifically stated or obvious from the context, the term "or" as used herein is understood to be inclusive. Unless specifically stated or obvious from the context, the terms "a / an" and "the" as used herein are understood to be singular or plural.
[0171] Unless specifically stated or apparent from the context, the term "about" as used herein is understood to be within the normal tolerance range of the art, such as within 2 standard deviations of the mean. As other examples, "about" may be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of a specified value.
[0172] The recitation of a list of chemical groups in any definition of a variable herein includes definitions of the variable as any single group or combination of the listed groups. The recitation of an embodiment of a variable or aspect herein includes the embodiment as any single embodiment or combination with any other embodiment or portion thereof.
[0173] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.
[0174] Example
[0175] The following are exemplary compounds of the present invention, which are provided by way of illustration and are not intended to limit the present invention. The present invention encompasses all compounds represented by general formula (I) and general formula (II), including salts thereof, hydrates thereof, geometric isomers thereof, optical isomers thereof, and polymorphic forms thereof. Those skilled in the art will be advised to make various modifications or changes within the spirit and scope of the present application.
[0176] Exemplary compounds of formula (I):
[0177]
[0178] wherein R2 is H, R3 is an aliphatic hydrocarbon chain of 8 carbons in the form of a double bond with one degree of unsaturation, R4 is a methyl group (—CH3), and R1 is as defined in Table 1.
[0179] Table 1: Compound numbers of formula (I) and corresponding R1 groups
[0180]
[0181] Exemplary compounds of formula (II):
[0182]
[0183] wherein R2 is H, R4 is methyl (-CH3), and R1 is as defined in Table 2.
[0184] Table 2: Compound numbers of formula (II) and corresponding R1 groups
[0185]
Claims
1. A compound of formula I or a salt thereof: in: R1 is an amino acid linked to the adjacent carbonyl moiety via an amide bond; R2 are each independently H or -COCH3; R3 is a saturated or unsaturated aliphatic hydrocarbon chain having 5-15 carbons; and R4 is H or -CH3.
2. The compound of claim 1, wherein the amino acid is taurine.
3. The compound of claim 1, wherein the amino acid is methionine, lysine or glutamine.
4. The compound according to claim 1, wherein the compound is the sodium Na of the amino acid + or potassium K + Salt.
5. A compound of formula II or a salt thereof in: R1 is an amino acid linked to the adjacent carbonyl moiety via an amide bond; R2 is each independently H or -COCH3; and R4 is H or -CH3.
6. The compound of claim 5, wherein the amino acid is taurine.
7. The compound of claim 5, wherein the amino acid is methionine, lysine or glutamine.
8. The compound according to claim 5, wherein the compound is the sodium Na of the amino acid + or potassium K + Salt.
9. A composition comprising a compound according to claim 1 in a pharmaceutically or cosmetically acceptable carrier.
10. The composition according to claim 9, further comprising a compound according to claim 5.
11. A composition comprising a compound according to claim 5 in a pharmaceutically or cosmetically acceptable carrier.
12. A method for improving the oral bioavailability of an amino acid in a subject, the method comprising orally administering to the subject a modified sophorolipid of formula I and / or formula II or a salt thereof, wherein R1 is an amino acid linked to an adjacent carbonyl moiety via an amide bond, R2 are each independently H or -COCH3, R3 are saturated or unsaturated aliphatic hydrocarbon chains having 5-15 carbons, and R4 are each independently H or -CH3.
13. The compound of claim 12, wherein the amino acid is taurine, methionine, lysine or glutamine.
14. A method of treating or preventing a disease, disorder or condition in a subject, the method comprising administering to the subject a modified sophorolipid of Formula I and / or Formula II or a salt thereof: wherein R1 is each independently an amino acid linked to an adjacent carbonyl moiety via an amide bond, R2 is each independently H or -COCH3, R3 is a saturated or unsaturated aliphatic hydrocarbon chain having 5-15 carbons, and R4 is each independently H or -CH3.
15. The method of claim 14, wherein the disease, disorder or condition is increased stress factors, and wherein the amino acid is methionine, lysine and / or glutamine.
16. The method of claim 14, wherein the disease, disorder or condition is a muscle disorder or disease, and wherein the amino acid is taurine.
17. The method of claim 14, wherein the disease, disorder or condition is a cardiovascular disorder or disease, and wherein the amino acid is taurine.
18. The method of claim 14, wherein the disease, disorder or condition is hypertension, and wherein the amino acid is taurine.
19. The method of claim 14, wherein the disease, disorder or condition is a central nervous system or peripheral nervous system disorder or disease, and wherein the amino acid is taurine.
20. The method of claim 14, wherein the disease, disorder or condition is a connective tissue disorder or disease, and Wherein the amino acid is taurine.
21. A method of improving muscle vitality in a subject, the method comprising administering to the subject in need of such improvement a modified sophorolipid of formula I and / or formula II or a salt thereof: wherein R1 is an amino acid connected to an adjacent carbonyl moiety via an amide bond, R2 is each independently H or -COCH3, R3 is a saturated or unsaturated aliphatic hydrocarbon chain having 5-15 carbons, and R4 is each independently H or -CH3; and Wherein the amino acid is taurine.
